Stock Research: NovoCure

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

NovoCure

NasdaqGS:NVCR JE00BYSS4X48
14
  • Value
    21
  • Growth
    51
  • Safety
    Safety
    27
  • Combined
    8
  • Sentiment
    41
  • 360° View
    360° View
    14
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) devices. The company operates in the medical device industry. It operates globally, with a license to market Optune in China, Hong Kong, Macau, and Taiwan. In the last fiscal year, the company had a market cap of $1,887 million, profits of $468 million, and revenue of $605 million, with 1488 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock NovoCure are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for NovoCure. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 51% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 27 means that the share price of NovoCure is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 73% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 21, which means that the company has a riskier financing structure than 79% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 41, indicating professional investors are more pessimistic about the stock than for 59% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 20 27 11
Growth
51 80 19 55
Safety
Safety
21 7 25 12
Sentiment
41 30 1 10
360° View
360° View
14 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
51 51 28 3
Opinions Change
50 40 9 26
Pro Holdings
n/a 23 6 72
Market Pulse
69 63 12 38
Sentiment
41 30 1 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 20 27 11
Growth
51 80 19 55
Safety Safety
21 7 25 12
Combined
8 17 6 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
4 4 4 4
Price vs. Earnings (P/E)
55 27 46 3
Price vs. Book (P/B)
22 11 28 12
Dividend Yield
1 1 1 1
Value
27 20 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
57 1 33 52
Profit Growth
31 74 6 52
Capital Growth
91 100 98 90
Stock Returns
25 84 3 7
Growth
51 80 19 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
2 1 6 12
Refinancing
77 62 93 67
Liquidity
1 7 8 4
Safety Safety
21 7 25 12

Similar Stocks

Discover high‑ranked alternatives to NovoCure and broaden your portfolio horizons.

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Vodafone

LSE:VOD
Country: United Kingdom
Industry: Wireless Telecommunication
Size: X-Large
Full Stock Analysis

Fresenius

XTRA:FRE
Country: Germany
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.